Spots Global Cancer Trial Database for pk
Every month we try and update this database with for pk cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors | NCT00447005 | Carcinoma | Axitinib (AG-01... | 20 Years - 75 Years | Pfizer | |
| A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | NCT02187744 | Early Breast Ca... | PF-05280014 Taxotere® Paraplatin® Trastuzumab-EU Taxotere® Paraplatin® | 18 Years - | Pfizer | |
| Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function | NCT01443481 | Solid Tumors Hepatic Impairm... | Dovitinib | 18 Years - | Novartis | |
| Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function | NCT01443481 | Solid Tumors Hepatic Impairm... | Dovitinib | 18 Years - | Novartis | |
| Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | NCT02316197 | Advanced Solid ... Chronic Lymphoc... | MSC2490484A (M3... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer | NCT01266954 | Solid Tumours | GSK2141795 | 18 Years - 85 Years | GlaxoSmithKline | |
| 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies | NCT00997945 | Advanced Solid ... | ZD4054 (Ziboten... | 50 Years - | AstraZeneca | |
| A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants | NCT03649165 | Neurofibromatos... Healthy Partici... | Treatment A Treatment B Treatment C Treatment D Acetaminophen | 18 Years - 45 Years | AstraZeneca | |
| Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer | NCT01324323 | Hematologic Mal... Malignant Lymph... | Romidepsin Rifampin | 18 Years - | Celgene | |
| Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy | NCT01938716 | Pancreatic Canc... | Gemcitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors | NCT01340547 | Advanced Solid ... | palifosfamide-t... Normal Saline | 18 Years - | Alaunos Therapeutics | |
| A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | NCT01216176 | Breast Cancer | Anastrozole AZD0530 (saraca... Placebo | 18 Years - | University of Miami | |
| Sorafenib Plus S-1 in Advanced Solid Tumors | NCT01128998 | Advanced Solid ... | Sorafenib S-1 | 20 Years - 75 Years | National Health Research Institutes, Taiwan | |
| A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01) | NCT02031991 | Healthy | PF-06439535 Avastin Avastin | 21 Years - 55 Years | Pfizer | |
| A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | NCT03665285 | Advanced or Met... Lung Cancer Breast Cancer Head and Neck S... Endometrial Can... Melanoma CRC Urothelial Carc... Cholangiocarcin... | NC318 | 18 Years - | NextCure, Inc. | |
| A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | NCT04875806 | Advanced or Met... Ovarian Cancer Non-small Cell ... Breast Cancer | NC762 | 18 Years - | NextCure, Inc. | |
| Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity | NCT02154022 | Cancer Solid Tumors Neoplasm | 2 Years - | National Institutes of Health Clinical Center (CC) | ||
| Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD) | NCT01479088 | Secondary Hyper... | Cinacalcet HCl | 2 Years - 18 Years | Istituto Giannina Gaslini | |
| Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function | NCT00652626 | MDS AML Solid Tumors Multiple Myelom... Non-Hodgkin's L... Hodgkin's Disea... | azacitidine | 18 Years - | Celgene | |
| A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | NCT05572684 | Advanced or Met... Microsatellite ... Microsatellite ... Microsatellite ... Ovarian Cancer Gastric Cancer Colo-rectal Can... Esophageal Canc... Endometrial Can... Head Neck Cance... Cervical Cancer Lung Cancer | NC410 pembrolizumab | 18 Years - | NextCure, Inc. | |
| A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies | NCT00981721 | Advanced Solid ... | cediranib (RECE... | 18 Years - | AstraZeneca | |
| Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors | NCT00874042 | Advanced Solid ... | Treatment with ... | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors | NCT00827177 | Advanced Solid ... | Treatment with ... | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function | NCT01443481 | Solid Tumors Hepatic Impairm... | Dovitinib | 18 Years - | Novartis | |
| A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | NCT04408599 | Advanced or Met... Ovarian Cancer Gastric Cancer Colo-rectal Can... | NC410 | 18 Years - | NextCure, Inc. | |
| Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors | NCT00447005 | Carcinoma | Axitinib (AG-01... | 20 Years - 75 Years | Pfizer | |
| TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer | NCT01455389 | Lung Cancer | DOTAP:Chol-TUSC... Erlotinib Dexamethasone Diphenhydramine | 18 Years - | Genprex, Inc. | |
| Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function | NCT00652626 | MDS AML Solid Tumors Multiple Myelom... Non-Hodgkin's L... Hodgkin's Disea... | azacitidine | 18 Years - | Celgene | |
| A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01) | NCT01603264 | Healthy | PF-05280014 Herceptin Herceptin | 18 Years - 55 Years | Pfizer | |
| TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer | NCT01455389 | Lung Cancer | DOTAP:Chol-TUSC... Erlotinib Dexamethasone Diphenhydramine | 18 Years - | Genprex, Inc. | |
| A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | NCT04875806 | Advanced or Met... Ovarian Cancer Non-small Cell ... Breast Cancer | NC762 | 18 Years - | NextCure, Inc. | |
| Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine | NCT01519011 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | oral azacitidin... oral azacitidin... | 18 Years - | Celgene | |
| A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies | NCT03440437 | Advanced Cancer Metastatic Canc... Squamous Cell C... | FS118 Paclitaxel | 18 Years - | invoX Pharma Limited | |
| The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors | NCT04312282 | Advanced Solid ... | Tesetaxel Tesetaxel Itraconazole Rifampin | 18 Years - | Odonate Therapeutics, Inc. | |
| A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | NCT02187744 | Early Breast Ca... | PF-05280014 Taxotere® Paraplatin® Trastuzumab-EU Taxotere® Paraplatin® | 18 Years - | Pfizer | |
| Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer | NCT01324310 | Hematologic Mal... Malignant Lymph... | Romidepsin Ketoconazole | 18 Years - | Celgene | |
| Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy | NCT01938716 | Pancreatic Canc... | Gemcitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity | NCT02154022 | Cancer Solid Tumors Neoplasm | 2 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
